US006573299B1

(12) **United States Patent**
Petrus

(10) **Patent No.: US 6,573,299 B1**
(45) **Date of Patent: Jun. 3, 2003**

(54) **METHOD AND COMPOSITIONS FOR TREATMENT OF THE AGING EYE**

(75) Inventor: **Edward J. Petrus**, Austin, TX (US)

(73) Assignee: **Advanced Medical Instruments**, Austin, TX (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/399,393**

(22) Filed: **Sep. 20, 1999**

(51) **Int. Cl.**[7] **A61K 31/20**
(52) **U.S. Cl.** **514/558**; 514/912
(58) **Field of Search** 514/558, 912

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,856,941 A 12/1974 Turner
4,296,130 A 10/1981 Herschler
4,342,784 A 8/1982 Havemeyer et al.
4,477,469 A 10/1984 Herschler
4,708,965 A 11/1987 Morgan
4,772,591 A 9/1988 Meisner
4,863,748 A 9/1989 Herschler
4,933,184 A 6/1990 Tsuk
4,938,969 A 7/1990 Schinitsky et al.
4,973,605 A 11/1990 Herschler
5,071,878 A 12/1991 Herschler
5,118,505 A 6/1992 Koltringer
5,156,852 A 10/1992 La Haye et al.
5,196,417 A * 3/1993 Dolling et al. 514/226.5
5,229,130 A 7/1993 Sharma et al.
5,238,933 A 8/1993 Catz et al.
5,254,343 A 10/1993 Parah et al.
5,266,594 A 11/1993 Dawson et al.
5,281,722 A 1/1994 Blaschke et al.
5,306,731 A 4/1994 Epstein
5,310,764 A 5/1994 Baranowitz et al.
5,334,612 A 8/1994 Kalden et al.
5,409,693 A 4/1995 Perricone
5,432,199 A 7/1995 Cavazza
5,449,688 A 9/1995 Wahl et al.
5,457,135 A 10/1995 Baranowitz et al.
5,468,476 A 11/1995 Ahluwalia et al.
5,470,874 A 11/1995 Lerner
5,482,965 A 1/1996 Rajadhyaksha
5,532,269 A 7/1996 Koltringer
5,545,614 A 8/1996 Stamler et al.
5,569,670 A 10/1996 Weischer et al.
5,585,402 A 12/1996 Moncada et al.
5,596,011 A 1/1997 Repine et al.
5,620,980 A 4/1997 Samour
5,643,587 A 7/1997 Scancarella et al.
5,650,429 A 7/1997 Conrad et al.
5,665,757 A 9/1997 Dunn et al.
5,667,791 A 9/1997 Hersh et al.
5,676,956 A 10/1997 Duffy et al.
5,691,380 A 11/1997 Mason et al.
5,723,451 A 3/1998 Majalli et al.
5,728,735 A 3/1998 Ulrich et al.
5,747,536 A 5/1998 Cavazza
5,766,873 A 6/1998 Noble et al.
5,780,693 A 7/1998 Bernhard et al.
5,786,342 A 7/1998 Carpenter et al.
5,789,396 A 8/1998 Blank et al.
5,792,449 A 8/1998 Bryce-Smith
5,804,594 A 9/1998 Murad
5,807,957 A 9/1998 Samour et al.
5,821,237 A 10/1998 Bissett et al.
5,824,659 A 10/1998 Strickland et al.
5,837,289 A 11/1998 Grasela et al.
5,846,996 A 12/1998 Fallick
5,871,769 A 2/1999 Fleming et al.
5,873,831 A 2/1999 Bernstein et al.
5,876,736 A 3/1999 Cohen et al.
5,883,128 A * 3/1999 Yu et al. 514/557
5,886,042 A 3/1999 Yu et al.
5,889,054 A 3/1999 Yu et al.
5,897,891 A 4/1999 Godfrey
5,916,912 A 6/1999 Ames et al.
5,922,331 A 7/1999 Mausner
5,922,346 A 7/1999 Hersh
5,925,348 A 7/1999 Riley et al.
5,925,620 A 7/1999 Ohlenschlager et al.
5,937,790 A 8/1999 Ito et al.
5,939,394 A 8/1999 Fleming et al.
5,945,447 A 8/1999 Fallick
6,103,756 A * 8/2000 Gorsek 514/458

OTHER PUBLICATIONS

Osborne DW, Henke JJ. Skin Penetration Enhancers Cited In the Technical Literature. *Pharmaceutical Technology* Nov. 1997 p 58–80.

Brechner RJ et al Ophthalmic Examination Among Adults With Diagnosed Diabetes Mellitus *JAMA* 1993 270(14)1714–18.

Rosenberg LA, Glaucoma; Early Detection and Therapy for Prevention of Vision Loss *American Family Physician* 1995 52(8) 2289–98.

Samples JR Pharmacologic Management of Glaucoma *Rational Drug Therapy* 1987 21(12)1–6.

Olson RJ, DeBry P, Zinc as a Treatment for Age–Related Macular Degeneration *J. Trace Elements in Experimental Medicine* 1998 11:137–145.

Mares–Pearlman J A et al. Assocation of Zinc and Antioxidant Nutrients With Age–Related Maculopathy. *Arch Ophthalmol* 1996 114:991–97.

(List continued on next page.)

Primary Examiner—Zohreh Fay

(57) **ABSTRACT**

This invention relates to a method for the prevention and treatment of orbital disorders associated with the aging eye in mammals by the application of a topical composition comprising a permeation enhancing amount of one or more penetration enhancers, and one or more bio-affecting agents which penetrate into the underlying tissues and into the vascular network of the orbit. Another object of this invention is the improvement of age-related changes to the eyelids such as dry skin, wrinkles, keratoses, age spots and pigmented skin lesions. It is a further object of this invention to prevent and treat cataract formation, glaucoma, diabetic retinopathy and macular degeneration.

5 Claims, No Drawings